Cwm LLC Raises Stake in Bruker Corporation $BRKR

Key Points

• Cwm LLC increased its stake in Bruker Corporation by 30.6% during the second quarter, bringing their total shares owned to 56,931 with a value of $2,346,000.
• Bruker reported $0.32 earnings per share for the last quarter, missing estimates by $0.01, and experienced a revenue decline of 0.4% compared to the previous year.
• The company also declared a quarterly dividend of $0.05 per share, reflecting a 0.5% yield, with a payout ratio of 38.46%.

Cwm LLC grew its stake in shares of Bruker Corporation (NASDAQ:BRKR - Free Report) by 30.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 56,931 shares of the medical research company's stock after purchasing an additional 13,335 shares during the quarter. Cwm LLC's holdings in Bruker were worth $2,346,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in BRKR. Fifth Third Bancorp boosted its stake in shares of Bruker by 54.2% during the first quarter. Fifth Third Bancorp now owns 1,109 shares of the medical research company's stock valued at $46,000 after purchasing an additional 390 shares during the period. Wealth Enhancement Advisory Services LLC lifted its stake in Bruker by 81.2% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 29,826 shares of the medical research company's stock worth $1,245,000 after acquiring an additional 13,367 shares during the period. Lecap Asset Management Ltd. purchased a new stake in Bruker in the first quarter worth about $2,714,000. Wealthquest Corp purchased a new stake in Bruker in the first quarter worth about $143,000. Finally, Pinnacle Bancorp Inc. purchased a new stake in Bruker in the first quarter worth about $29,000. 79.52% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Cynthia M. Friend sold 3,535 shares of the company's stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $32.25, for a total transaction of $114,003.75. Following the transaction, the director owned 18,016 shares in the company, valued at $581,016. This represents a 16.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 27.30% of the stock is currently owned by company insiders.

Bruker Stock Performance

Shares of Bruker stock opened at $36.98 on Friday. Bruker Corporation has a one year low of $28.53 and a one year high of $64.64. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.70 and a current ratio of 1.61. The company has a market capitalization of $5.61 billion, a PE ratio of 71.12, a P/E/G ratio of 5.18 and a beta of 1.20. The company has a 50-day simple moving average of $33.48 and a two-hundred day simple moving average of $36.98.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The medical research company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). Bruker had a net margin of 2.31% and a return on equity of 17.89%. The company had revenue of $797.40 million for the quarter, compared to analyst estimates of $811.17 million. During the same quarter last year, the company earned $0.52 EPS. The business's revenue was down .4% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. Research analysts expect that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 3rd. Stockholders of record on Tuesday, September 23rd were issued a dividend of $0.05 per share. The ex-dividend date was Tuesday, September 23rd. This represents a $0.20 annualized dividend and a dividend yield of 0.5%. Bruker's dividend payout ratio is 38.46%.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on BRKR shares. Bank of America lowered their price objective on shares of Bruker from $61.00 to $50.00 and set a "buy" rating for the company in a research note on Thursday, June 26th. Jefferies Financial Group set a $60.00 price objective on shares of Bruker and gave the stock a "buy" rating in a research note on Monday, August 4th. Stifel Nicolaus set a $40.00 price objective on shares of Bruker and gave the stock a "hold" rating in a research note on Tuesday, August 5th. Wells Fargo & Company reduced their target price on shares of Bruker from $60.00 to $50.00 and set an "overweight" rating for the company in a report on Tuesday, August 5th. Finally, Barclays reduced their target price on shares of Bruker from $43.00 to $40.00 and set an "overweight" rating for the company in a report on Thursday, October 2nd. Five equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Bruker currently has an average rating of "Hold" and an average price target of $51.00.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Corporation (NASDAQ:BRKR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.